GPX4 and neoplasm: Increased expression of IRF2, GPX4, and TIRAP, for example, has been linked to enhanced susceptibility of tumor cells to chemotherapeutic agents such as TP-3654, nelarabine, S-49076, ZM-336372, XL-147T, and tivantinib.